Role of IL-33 and IL-35 in the Pathogenesis of Rheumatoid Arthritis
References
- McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet Lond Engl. 2017;389(10086):2328-37.
- Catrina AI, Joshua V, Klareskog L, Malmström V. Mechanisms involved in triggering rheumatoid arthritis. Immunol Rev. 2016;269(1):162-74.
- Makuch, S.; Więcek, K.; Woźniak, M. The Immunomodulatory and Anti-Inflammatory Effect of Curcumin on Immune Cell Populations, Cytokines, and In Vivo Models of Rheumatoid Arthritis. Pharmaceuticals 2021;14(4):309.
- Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15
- Noack, M.; Miossec, P. Selected cytokine pathways in rheumatoid arthritis. Semin. Immunopathol. 2017, 39, 365-83
- Achudhan D, Liu SC, Lin YY, Huang CC, Tsai CH, Ko CY, Chiang IP, Kuo YH, Tang CH. Antcin K Inhibits TNF-α, IL-1β and IL-8 Expression in Synovial Fibroblasts and Ameliorates Cartilage Degradation: Implications for the Treatment of Rheumatoid Arthritis. Front Immunol. 2021;12:790925.
- Kumar, V.; Kanwar, J.R.; Verma, A.K. Rheumatoid arthritis: Basic pathophysiology and role of chitosan nanoparticles in therapy. In Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents; Singh, M.R., Singh, D., Kanwar, J.R., Chauhan, N.S., Eds.; Academic Press: Cambridge, MA, USA, 2020; pp. 481-507. ISBN 978-0-12-819666-3
- Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-32.
- Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(1):9-17.
- Liew FY, Girard J-P, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676-89.
- Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90.
- Baekkevold ES, Roussigné M, Yamanaka T, Johansen F-E, Jahnsen FL, Amalric F, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163(1):69-79.
- Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T, et al. Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem. 2011;286(22):20078-86.
- Carriere V, Roussel L, Ortega N, Lacorre D-A, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007;104(1):282-7.
- Travers J, Rochman M, Miracle CE, Habel JE, Brusilovsky M, Caldwell JM, et al. Chromatin regulates IL-33 release and extracellular cytokine activity. Nat Commun. 2018;9(1):3244.
- Roussel L, Erard M, Cayrol C, Girard J-P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008;9(10):1006-12.
- Cayrol C, Girard J-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31-7.
- Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281(1):154-68.
- Cayrol C, Girard J-P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. 2009;106(22):9021-6.
- Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84-98.
- Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard J-P, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A. 2012;109(5):1673-8.
- Moussion C, Ortega N, Girard J-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel “alarmin”? PloS One. 2008;3(10):e3331.
- Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol Baltim Md 1950. 2009;183(8):5094-103.
- Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013;60:16-26.
- Löhning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A. 1998;95(12):6930-5.
- Schiering C, Krausgruber T, Chomka A, Fröhlich A, Adelmann K, Wohlfert EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564-8.
- Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TKA, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367-70.
- Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol Baltim Md 1950. 2009;183(10):6469-77.
- Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol Baltim Md 1950. 1998;161(9):4866-74.
- Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484-90.
- Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol Baltim Md 1950. 2008;181(9):5981-9.
- Smithgall MD, Comeau MR, Yoon B-RP, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20(8):1019-30.
- Bonilla WV, Fröhlich A, Senn K, Kallert S, Fernandez M, Johnson S, et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science. 2012;335(6071):984-9.
- Peine M, Marek RM, Löhning M. IL-33 in T Cell Differentiation, Function, and Immune Homeostasis. Trends Immunol. 2016;37(5):321-33.
- Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol Baltim Md 1950. 2008;181(7):4780-90.
- Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. 2009;113(7):1526-34.
- Komai-Koma M, Wang E, Kurowska-Stolarska M, Li D, McSharry C, Xu D. Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12. Immunobiology. 2016;221(3):412-7.
- Baumann C, Bonilla WV, Fröhlich A, Helmstetter C, Peine M, Hegazy AN, et al. T-bet- and STAT4- dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci U S A. 2015;112(13):4056-61.
- Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993;318(1):83-7.
- Liu X, Hammel M, He Y, Tainer JA, Jeng U-S, Zhang L, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A. 2013;110(37):14918-23.
- Molofsky AB, Savage AK, Locksley RM. Interleukin- 33 in Tissue Homeostasis, Injury, and Inflammation. Immunity. 2015;42(6):1005-19.
- Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107(5):650-8.
- Duan L, Chen J, Zhang H, Yang H, Zhu P, Xiong A, et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3+ regulatory T-cell responses in mice. Mol Med Camb Mass. 2012;18:753-61.
- Pavlovic S, Petrovic I, Jovicic N, Ljujic B, Miletic Kovacevic M, Arsenijevic N, et al. IL-33 Prevents MLDSTZ Induction of Diabetes and Attenuate Insulitis in Prediabetic NOD Mice. Front Immunol. 2018;9:2646.
- Macedo RBV, Kakehasi AM, Melo de Andrade MV. IL33 in rheumatoid arthritis: potential contribution to pathogenesis. Rev Bras Reumatol. 2016;56(5):451-7
- Dong Y, Zhong J, Dong L. IL-33 in Rheumatic Diseases. Front Med (Lausanne). 2021 ;8:739489
- Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin- 1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505-15.
- Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol. 2010;37(1):18-25.
- Aliaa M. Abd El-Aziz Faraga , Nagat M. El-Gazzarb , Marwa A.Abo El Hawab , Mohamed A.Saad Attia. Study of interleukin 33 in rheumatoid arthritis versus osteoarthritis patients. Egyptian Rheumatology & Rehabilitation 2017;44:159-63.
- Salama AA, Mahmoud AB, Al-Sharaki DR, Gomah AF. Role of interleukin-33 in rheumatoid arthritis patients from Menoufia University Hospitals. Menoufia Med J 2017;30:952-7
- Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol Baltim Md 1950. 2004;173(1):145-50.
- Xu D, Jiang H-R, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008;105(31):10913-8.
- Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin- 33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60(3):738-49.
- Biton J, Khaleghparast Athari S, Thiolat A, Santinon F, Lemeiter D, Hervé R, et al. In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis. J Immunol Baltim Md 1950. 2016;197(5):1708-19.
- Martin P, Talabot-Ayer D, Seemayer CA, Vigne S, Lamacchia C, Rodriguez E, et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther. 2013;15(1):R13.
- Athari SK, Poirier E, Biton J, Semerano L, Hervé R, Raffaillac A, et al. Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Arthritis Res Ther. 2016;18(1):143.
- Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-α dependent effects in synovial fibroblasts. Int J Mol Med. 2012;29(4):530-40.
- Hong Y-S, Moon S-J, Joo Y-B, Jeon C-H, Cho M-L, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL- 33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011;26(9):1132-9.
- Tang S, Huang H, Hu F, Zhou W, Guo J, Jiang H, et al. Increased IL-33 in Synovial Fluid and Paired Serum Is Associated with Disease Activity and Autoantibodies in Rheumatoid Arthritis. Clin Dev Immunol. 2013;2013:985301.
- Devergne O, Birkenbach M, Kieff E. Epstein-Barr virusinduced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A. 1997;94(22):12041-6.
- Xin PL, Jie LF, Cheng Q, Bin DY, Dan CW. Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis. Front Pharmacol. 2021;12:655114.
- Zhang J, Zhang Y, Wang Q, Li C, Deng H, Si C, et al. Interleukin-35 in immune-related diseases: protection or destruction. Immunology. 2019;157(1):13-20.
- Belladonna ML, Grohmann U. Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents. Biotechnol Genet Eng Rev. 2013;29:149-74.
- Zhang FF, Liu S, John EM, Must A, Demark-Wahnefried W. Diet quality of cancer survivors and noncancer individuals: Results from a national survey. Cancer. 2015;121(23):4212-21.
- Li X, Shao Y, Sha X, Fang P, Kuo Y-M, Andrews AJ, et al. IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (Histone 3 Lysine 14). Arterioscler Thromb Vasc Biol. 2018;38(3):599-609.
- Dambuza IM, He C, Choi JK, Yu C-R, Wang R, Mattapallil MJ, et al. IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease. Nat Commun. 2017;8(1):719.
- Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, et al. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine. 2014;69(1):87-93.
- Li Y, Jie Y, Wang X, Lu J. Serum IL-35 is decreased in overweight patients with rheumatoid arthritis: its correlation with Th1/Th2/Th17-related cytokines. BMC Immunol. 2021;22(1):42.
- Niedbala W, Wei X-Q, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37(11):3021-9.
- Li Y, Yao L, Liu S, Wu J, Xia L, Shen H, et al. Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity. J Investig Med Off Publ Am Fed Clin Res. 2019;67(3):707-10.
- Wang D, Lei L. Interleukin-35 regulates the balance of Th17 and Treg responses during the pathogenesis of connective tissue diseases. Int J Rheum Dis. 2021;24(1):21-7.
- Xie Q, Xu W-D, Pan M, Lan Y-Y, Liu X-Y, Su L-C, et al. Association of IL-35 expression and gene polymorphisms in rheumatoid arthritis. Int Immunopharmacol. 2021;90:107231.
- Wang X, Zhong W. Isorhamnetin attenuates collageninduced arthritis via modulating cytokines and oxidative stress in mice. Int J Clin Exp Med. 2015;8(9):16536-42.
- Li Y, Li D, Li Y, Wu S, Jiang S, Lin T, et al. Interleukin- 35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2016;27(4):1537-46.
- Yago T, Nanke Y, Kawamoto M, Kobashigawa T, Yamanaka H, Kotake S. IL-35 inhibits human osteoclastogenesis from monocytes induced by receptor-activator of NF-κB ligand. Cent-Eur J Immunol. 2018;43(2):148-54.
DOI: https://doi.org/10.2478/sjecr-2022-0037 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)
Language: English
Submitted on: Jan 23, 2022
Accepted on: Mar 16, 2022
Published on: Jan 27, 2023
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2023 Jasmina Jocic, Sladjana Pavlovic, Aleksandra Tomic Lucic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.